Literature DB >> 11793367

Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Hiroki Kuniyasu1, Naohide Oue, Atsuko Wakikawa, Hideo Shigeishi, Norimasa Matsutani, Kazuya Kuraoka, Reiko Ito, Hiroshi Yokozaki, Wataru Yasui.   

Abstract

The receptor for advanced glycation end-products (RAGE) is a newly recognized factor regulating cancer cell invasion and metastasis. This study investigated the expression of RAGE in gastric carcinomas and its association with invasion and metastasis. Of eight gastric cancer cell lines examined, seven constitutively expressed RAGE messenger ribonucleic acid (mRNA), MKN45 being the exception. RAGE protein expression of MKN28 cells treated with RAGE antisense S-oligodeoxynucleotide was nine times less than that of sense S-oligodeoxynucleotide-treated cells. Growth of cells under RAGE antisense S-oligodeoxynucleotide treatment was not different from that seen under sense S-oligodeoxynucleotide treatment in MKN28 (a cell line producing high levels of RAGE) and MKN45 (a non-RAGE-expressing cell line). RAGE antisense S-oligodeoxynucleotide treatment suppressed the invasive activity of RAGE-positive MKN28 cells, as estimated by in vitro invasion assay. The number of MKN28 cells invading the type IV collagen-coated membrane under RAGE antisense S-oligodeoxynucleotide treatment was significantly lower than under RAGE sense S-oligodeoxynucleotide treatment (p<0.0001). In contrast, antisense and sense S-oligodeoxynucleotide-treated RAGE-negative MKN45 cells showed no difference. A wound-healing assay showed that no RAGE antisense S-oligodeoxynucleotide-treated MKN28 cells migrated into the scraped area, whereas sense S-oligodeoxynucleotide-treated cells showed many budding nests in the scraped area. Immunohistochemistry of gastric carcinoma tissue showed that 62 (65%) of the 96 cases examined were RAGE-positive and that poorly differentiated adenocarcinomas preferentially expressed RAGE protein (38/42, 90%) (p<0.0001). Strong RAGE immunoreactivity was also correlated with depth of invasion and lymph node metastasis (p<0.0001). RAGE-positive cancer cells tended to be distributed at the invasive front of primary tumours and were detected in all metastatic foci in lymph nodes. In contrast, a major RAGE ligand, amphoterin, was expressed in 82 (85%) of the 96 cases, regardless of histological type and disease progression. RAGE expression appears to be closely associated with invasion and metastasis in gastric cancer. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793367     DOI: 10.1002/path.1031

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  112 in total

1.  The G82S polymorphism promotes glycosylation of the receptor for advanced glycation end products (RAGE) at asparagine 81: comparison of wild-type rage with the G82S polymorphic variant.

Authors:  Sun Jin Park; Torsten Kleffmann; Paul A Hessian
Journal:  J Biol Chem       Date:  2011-04-21       Impact factor: 5.157

2.  High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

Authors:  Wei Jiang; Zhiming Wang; Xinying Li; Xuegong Fan; Yankun Duan
Journal:  Pathol Oncol Res       Date:  2011-09-07       Impact factor: 3.201

3.  Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer.

Authors:  Christian J Konopka; Marcin Woźniak; Jamila Hedhli; Anna Siekierzycka; Jarosław Skokowski; Rafał Pęksa; Marcin Matuszewski; Gnanasekar Munirathinam; Andre Kajdacsy-Balla; Iwona T Dobrucki; Leszek Kalinowski; Lawrence W Dobrucki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-03-12       Impact factor: 9.236

4.  Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer.

Authors:  Hongmei Wang; Yongchun Li; Wencheng Yu; Liqing Ma; Xia Ji; Wei Xiao
Journal:  Oncol Lett       Date:  2015-05-12       Impact factor: 2.967

5.  Colon cancer cell-derived high mobility group 1/amphoterin induces growth inhibition and apoptosis in macrophages.

Authors:  Hiroki Kuniyasu; Seiji Yano; Takamitsu Sasaki; Tomonori Sasahira; Sabro Sone; Hitoshi Ohmori
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

6.  Pro-metastatic signaling of the trans fatty acid elaidic acid is associated with lipid rafts.

Authors:  Shingo Kishi; Rina Fujiwara-Tani; Yi Luo; Isao Kawahara; Kei Goto; Kiyomu Fujii; Hitoshi Ohmori; Chie Nakashima; Takamitsu Sasaki; Hiroki Kuniyasu
Journal:  Oncol Lett       Date:  2018-01-17       Impact factor: 2.967

7.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

8.  Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE).

Authors:  Lana E Hanford; Jan J Enghild; Zuzana Valnickova; Steen V Petersen; Lisa M Schaefer; Todd M Schaefer; Todd A Reinhart; Tim D Oury
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

9.  Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels.

Authors:  Xiugui Sheng; Xuelian Du; Xiaoling Zhang; Dapeng Li; Chunhua Lu; Qinshui Li; Zhifang Ma; Quqing Song; Cong Wang
Journal:  Croat Med J       Date:  2009-10       Impact factor: 1.351

10.  Serum high mobility group box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer.

Authors:  Hye Won Chung; Sang-Guk Lee; Heejung Kim; Duck Jin Hong; Jae Bock Chung; David Stroncek; Jong-Baeck Lim
Journal:  J Transl Med       Date:  2009-05-28       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.